Status:

UNKNOWN

Effect of Nuts vs. a Wheat Bran Muffin in Type 2 Diabetes

Lead Sponsor:

University of Toronto

Conditions:

Type 2 Diabetes

Cardiovascular Disease

Eligibility:

All Genders

21+ years

Phase:

PHASE2

Brief Summary

To determine if tree nuts (Almonds, Hazelnuts, Pistachios, Peanuts, Macadamia nuts, Pecans, Walnuts and Cashews) improve glycemic control in type 2 diabetes, as assessed by HbA1c and serum fructosamin...

Detailed Description

The investigators wish to study the effect of nuts on glycemic control and to confirm their lipid lowering effects in type 2 diabetes. The consumption of nuts with their high unsaturated fat, vegetabl...

Eligibility Criteria

Inclusion

  • Men and post menopausal women with type 2 diabetes treated with diet plus oral hypoglycemic agents (sulfonylureas (glyburide), biguanides (metformin), Thiazolidinediones (TZDs) and new secretagogues (Repaglinide)) at a stable dose for at least 3 months prior to starting the study;
  • HbA1c of 6.5 to 8.0% as a compromise between those whose levels are acceptable and the level which is currently considered unacceptable.
  • Diabetes diagnosed \>6 months prior to randomization
  • Weight stable within 3% body weight \>2 months.

Exclusion

  • Use of acarbose
  • Use of Insulin
  • Known nut allergies
  • Clinically significant gastroparesis
  • Use of steroids
  • Presence of GI disease (celiac disease, ulcerative colitis, and Crohns)
  • Major cardiovascular event (stroke or myocardial infarction)
  • Major surgery \< 6 months prior to randomization
  • Presence of major debilitating disorder such as clinically significant liver disease (not including non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH) but including cirrhosis, infectious hepatitis (B and C), aspartate transaminase (AST) or alanine transaminase (ALT) \> 130 IU/L)
  • Renal failure (high creatinine \> 150 mmol/L)
  • Serum triglyceride \> 6 mmol/L.
  • Patients currently undergoing treatment for cancer with the exception of non-melanoma skin cancer, but not high risk patients or those whose treatment has been successfully completed.

Key Trial Info

Start Date :

December 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT00410722

Start Date

December 1 2006

Last Update

January 9 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

St. Michael's Hospital

Toronto, Ontario, Canada, M5C 2T2